Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.

[1]  J. Galvin,et al.  Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[2]  C. Simone,et al.  Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. , 2017, Practical radiation oncology.

[3]  B. Loo,et al.  Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. , 2017, Seminars in radiation oncology.

[4]  Guohua Yang,et al.  Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer , 2017, Journal of Cancer.

[5]  S. Houshmand,et al.  PET-Based Thoracic Radiation Oncology. , 2016, PET clinics.

[6]  Jian Wang,et al.  Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells , 2016, Oncotarget.

[7]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  S. Hahn,et al.  A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells , 2015, PloS one.

[9]  C. Chapman,et al.  Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. , 2014, Cancer research.

[10]  T. Guzzo,et al.  Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy , 2014, Cancer biology & therapy.

[11]  A. Ward,et al.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer. , 2014, Journal of thoracic disease.

[12]  Suresh Senan,et al.  High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  T. Molina,et al.  Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method , 2011, International journal of cancer.

[15]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[16]  Max Dahele,et al.  Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Y. Tamaki,et al.  A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients , 2011, Breast Cancer Research and Treatment.

[18]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Togashi,et al.  Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  C. Yiannoutsos,et al.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[21]  S. Kyo,et al.  A simple biological imaging system for detecting viable human circulating tumor cells. , 2009, The Journal of clinical investigation.

[22]  S. Kyo,et al.  Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus. , 2009, International journal of oncology.

[23]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[24]  Youngwook Kim,et al.  Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. , 2009, Anticancer research.

[25]  E. Kunieda,et al.  Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[26]  Mei Wang,et al.  Fluctuation of circulating tumor cells in patients with lung cancer by real-time fluorescent quantitative-PCR approach before and after radiotherapy. , 2005, Journal of cancer research and therapeutics.

[27]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[28]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[29]  C. Simone,et al.  Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results , 2015, Cancer.